Back to today’s briefing

Story perspectives

Roflumilast Foam Offers Hope for Psoriasis Patients

5/10/2025

36 2

Summary

Story summary

A groundbreaking Phase 3 clinical trial revealed that roflumilast foam 0.3% offers a promising solution for moderate-to-severe psoriasis, with 66.4% of 432 participants achieving clear skin on their scalp. This steroid-free treatment not only alleviates symptoms quickly but also holds the potential for FDA approval by 2025, bringing hope to many suffering from this condition.

1 of 1

Story summary

A groundbreaking Phase 3 clinical trial revealed that roflumilast foam 0.3% offers a promising solution for moderate-to-severe psoriasis, with 66.4% of 432 participants achieving clear skin on their scalp. This steroid-free treatment not only alleviates symptoms quickly but also holds the potential for FDA approval by 2025, bringing hope to many suffering from this condition.